
ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ã®DNAæ±æãFDAãç¬èªèª¿æ»
å èšäºã¯ãã¡ããã/Click here to read the original article.
2024幎12æ29æ¥ããJournal of High School Scienceãèªã«æ²èŒããããã®æ»èªä»ãç ç©¶ã¯ã3人ã®é«æ ¡çãå·çããFDAã®ç§åŠè ã®ç£ç£ã®äžãFDAã®ç 究宀ã§è¡ãããããã®çºèŠã«ãããCOVID-19ã¯ã¯ãã³ã®äžæåæ¢ãæ±ãã声ãåã³é«ãŸã£ãã
髿 ¡çãç±³åœé£åå»è¬åå±ïŒFDAïŒã®ç ç©¶æã§è¡ã£ãæ»èªä»ãç ç©¶ã«ããããã¡ã€ã¶ãŒç€Ÿã®mRNA COVID-19ã¯ã¯ãã³ã«é«ã¬ãã«ã®DNAæ··å ¥ãããããšã確èªãããã
ãã®ç ç©¶ã¯ãããŒãžãã¢å·ã¯ãªããã³ã«ããã»ã³ã¿ãŒãã«é«æ ¡ã®3人ã®çåŸãå·çããFDAã®ç§åŠè ã®ç£ç£äžã§è¡ãããã
ãã®ç ç©¶ãæåã«å ±éããã®ã¯ã調æ»å»çã¬ããŒã¿ãŒã®ããªã¢ã³ãã»ããã·å士ã§ããã
ã¡ãªãŒã©ã³ãå·ã«ããFDAã®ãã¯ã€ãã»ãªãŒã¯ã»ãã£ã³ãã¹ã§è¡ããããã®ç ç©¶ã§ã¯ããã¡ã€ã¶ãŒç€Ÿã®COVID-19ã¯ã¯ãã³ã«æ®åããDNAã®ã¬ãã«ããèŠå¶äžã®å®å šéçã®6åãã470åã§ããããšã倿ãããåŠçãã¡ã¯ãã®ã¯ã¯ãã³ã®2ã€ã®ãããããã¹ãããã1åæäžããã10ngïŒããã°ã©ã ïŒãè¶ ããã¬ãã«ã®æ®çDNA ããå«ãŸããŠããããšãçºèŠããã
ãæ®åããå°ããªDNAæçãããããæœåšçãªå¥åº·ãªã¹ã¯ã¯çŸåšã®ãšããäžæã§ãã "ãšç ç©¶ã¯è¿°ã¹ãŠãããããããèè ãã¯ãDNAæ±æã¯æ¿å ¥çªç¶å€ç°èªçºãããªãã¡ã¬ã³ã®åå ãšãªãDNAã®çªç¶å€ç°ãåŒãèµ·ããå¯èœæ§ããããšãè¿°ã¹ãŠããã
å æããThe Defender In-Depthãã§ã2023幎ã«åããŠäºé²æ³šå°ã«DNAãæ··å ¥ããŠããããšã確èªããã±ãã³ã»ããã«ãŒãã³ã¯ãã¯ã¯ãã³ã«æ··å ¥ããŠããDNAã¯ããã²ãã ã«çµã¿èŸŒãŸããã²ãã ã®ç Žå£ãåŒãèµ·ããå¯èœæ§ããã......ãããã¯ãããã«é¢ä¿ããä»ã®éºäŒåãç Žå£ããå¯èœæ§ããã ããããå¥åº·è¢«å®³ãããããå¯èœæ§ããããšè¿°ã¹ãã
FDAã¯ãã®ç ç©¶ã«ã€ããŠã®ã³ã¡ã³ããè€æ°åæ±ããããè¿çã¯ãªãã£ãã
COVIDã¯ã¯ãã³ã¯ãçŽã¡ã«ååãããªããã°ãªããªãã
ããã·æ°ã¯Substackã«ããã®æ°ããªèª¿æ»çµæã¯ããããŸã§èŠå¶åœå±ã¯ãéå°ãªDNAæ±æã«é¢ããæžå¿µã¯æ ¹æ ããªããšããŠããã
ãŸãããã®èª¿æ»çµæã¯ãç±³åœãã«ããããªãŒã¹ãã©ãªã¢ããã€ãããã©ã³ã¹ã®ç¬ç«ããç ç©¶æã以åã«çºè¡šããå ±åæžãšãäžèŽããŠãããšããã
ã¡ãã£ã·ãã«ã»ã²ããã¯ã¹ç€Ÿã®åµèšè ã§ããããã«ãŒãã³æ°ã¯ã8ã€ã®ç ç©¶ã§å¶éå€ãè¶ ããDNAãæ€åºããããšããã£ãã§ã³ããŒãçŽã«èªã£ããã倿°ã®ãããã調æ»ããŠããç ç©¶ã¯ã»ãšãã©ãªãã®ã§ãããããã®ç ç©¶ã¯çžå çãªãã®ã§ãã
ç«åŠè ãã³ã©ã¹ã»ãã¥ã«ã·ã£ãŒã¯ãããã®èšŒæ ã«ç §ãããŠãCOVID-19éºäŒå泚å°ã¯ããããªã被害ããå ¬è¡ãå®ãããã«ãçŽã¡ã«ååãããªããã°ãªããªã ããšè¿°ã¹ãã
ãã€ãªãã¯ãããžãŒäŒç€ŸVaxine Pty Ltd.ã®ãã£ã¬ã¯ã¿ãŒããã³ã©ã€ã»ããããã¹ããŒå士ã¯ãä»åã®èª¿æ»çµæã¯ ãæ±ºå®çãªèšŒæ ãã§ããããFDAããããã®ããŒã¿ãèªèããŠããããšãæç¢ºã«ç€ºããŠãã ããšããã·æ°ã«èªã£ãã
äžçä¿å¥äŒè°éå¶å§å¡äŒã®ã¡ã³ããŒã§ããã¯ãªã¹ããã»ãããå士ãåæèŠã§ããã圌ã¯èšãïŒ
ããããŸã§ã®ãšããããšãŒãããããªãŒã¹ãã©ãªã¢ãã¢ã¡ãªã«ã®ä¿å¥èŠå¶å§å¡äŒã¯ãåœéçã«ç¥ãããç ç©¶ããŒã ã«ãã9ã€ã®ç ç©¶ã«ãããããããCOVID-19泚å°ã«ããããã©ã¹ããDNAæ··å ¥ã«ãããªã¹ã¯ãåŠå®ããŠããŸãã
ããã¹ãŠã®ããŒã ãããã®æ±æã¯äžç人å£ã®4åã®3ã«èš±å®¹ã§ããªããªã¹ã¯ããããããšçµè«ã¥ããŠããããããŸã§ã®ãšããã3ã€ã®ããŒã ããã现èãžã®çµã¿èŸŒã¿ãå®èšŒããŠãããæ³šå°ããããã¹ãŠã®äººã«ã©ã®çšåºŠèµ·ãã£ãŠããã®ãã調æ»ããå¿ èŠããããŸããã
ããã«ãŒãã³ã«ããã°ãFDAã¯é·ãéãmRNA COVID-19ã¯ã¯ãã³ãããããå±éºæ§ã®èšŒæ ãç¡èŠããŠãããšããã
ããããã®æ³šå°ãäžæ¢ããåºæºã¯ãDNAæ±æãæåã«çºèŠããããã£ãšåã«ç¢ºç«ãããŠããŸããããç§ã¯ã補é å·¥çšã«å€§ããªã°ãã€ããããããšã瀺ã蚌æ ããFDAã«ããã¯ã©ã¹1ã®å³æååã®æ ¹æ ãšãªãããšãæãã§ãããFDAã¯çŸåšã殺å·åã®ãªããã¢ã¹ãã¬ãŒã®ã¯ã©ã¹1ãªã³ãŒã«ã«è¿œãããŠããã
ã¯ã©ã¹1ãªã³ãŒã«ã¯ããéå補åã®äœ¿çšãŸãã¯æé²ããé節ãªå¥åº·è¢«å®³ãŸãã¯æ»äº¡ãåŒãèµ·ããåççãªå¯èœæ§ãããç¶æ³ ããå«ãã
ããã·æ°ã«ããã°ããFDAã¯ä»é±äžã«ãã®èª¿æ»çµæã«ã€ããŠã³ã¡ã³ãããäºå®ã§ãããããããFDAã¯ãŸã èŠåãçºããããšãã圱é¿ãåããããããååããããšããå®å šåºæºãè¶ ãããã€ã¢ã«ãã©ã®ããã«ããŠåžå Žã«åºåã£ãã®ãã説æããããšãããŠããªããã
ãããã¯ãããã·ã2024幎9æã«FDAã«DNAæ··å ¥ã®èšŒæ ãæåºããFDAã調æ»ãéå§ããã®ãããããã¯mRNAã¯ã¯ãã³ã®è£œé æ¥è ã«ãããªããã¹ããèŠè«ããã®ããå°ããããšãææããã
ããã®èŠæ±ããã¯äœãåŸãããªãã£ããã9ã€ã®ç ç©¶ã§ãã®æ·±å»ãªæ±æã蚌æãããä¿å¥èŠå¶å§å¡äŒãžã®åäžã®èŠè«ãäœã®çµæã«ãã€ãªãããªãã£ãã®ã§ãæã ã¯ãã®åæ©ã«ã€ããŠå°ããªããã°ãªããªãã
ãã«ãã¬ã³ãºã»ãã«ã¹ã»ãã£ãã§ã³ã¹ïŒCHDïŒã®æé«ç§åŠè²¬ä»»è ã§ãããã©ã€ã¢ã³ã»ããã«ãŒå士ã¯ãã¯ã¯ãã³ãå°å ¥ãããŠãã4幎äœãã®éã«ãFDAãèŠéããŠãããšæãããããšã髿 ¡çãçºèŠãããšããç®èã«èšåããã
ãFDAã®èŠå¶åœå±ã®ä»äºãFDAã®åŠçç ç©¶è ããã£ãŠããã®ã¯ç®èãªããšã§ããã髿 ¡çã®ç§åŠç ç©¶ãç¹éããç¡åã®éèªã§ããã®æ±æã«ã€ããŠäžè¬ã«ç¥ããããŠããã®ã¯ææ ®ãã¹ãããšã§ããFDAã¯ä»ã©ãã«ããã®ãããããªããã®ããšãäžè¬å€§è¡ã«ç¥ãããªãã£ãã®ãããšåããã°ãªããªããã
ããã·æ°ã¯ããã®æ°ããç ç©¶çµæã®æçŸ©ã¯ããããFDAã®æœèšã§è¡ãããç ç©¶ã«ãããã®ã§ããããšã«ãããšè¿°ã¹ãã
ãmRNAã¯ã¯ãã³ã®DNAæ··å ¥ãå ¬çæ©é¢ã®ç ç©¶å®€ã§æ€èšŒãããæ»èªä»ãåŠè¡èªã§çºè¡šãããä»ãç¡èŠããããšã¯é£ãããªã£ããããŸããã¯ã¯ãã³è£œé æ¥è ãšèŠå¶åœå±ã¯äžå®å®ãªç«å Žã«ç«ããããããšã«ãªãã